VC Investment More Than Doubles in Q2, Driven by Megadeals

Investor appetite for “megadeals” of $100 million or more grew during the second quarter, helping explain why biopharma venture capital investment more than doubled compared with a year ago, even as the number of deals stayed flat, according to a report released this week.Investors raised $4.047 billion in 126 biopharma VC deals during Q2 2018, according to the most recent quarterly PwC/CB Insights MoneyTree™ Report. That’s 117% above the $1.867 billion recorded for the s